Shreya Badhrinarayanan

机构：Pfizer (United States), The Fertilizer Institute · ORCID：0000-0002-7159-098X

发表论文 34 篇 · 总被引 2789 次 · h-index 17

代表论文

• Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial (2021 · The Lancet · 被引 565)
• Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial (2021 · The Lancet · 被引 524)
• Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial (2022 · The Lancet · 被引 384)
• Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis (2022 · The Lancet · 被引 335)
• Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial (2021 · The Lancet · 被引 292)
• Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial (2023 · The Lancet · 被引 132)